Regulator reaffirms impropriety of taking dog vermicide to treat cancer (2019)

News Report · Lee Han-soo (Korea Biomedical Review), reporting the Ministry of Food and Drug Safety · October 28, 2019

Lee Han-soo (Korea Biomedical Review), 2019-10-28: The Korean food-safety ministry's detailed warning against fenbendazole for cancer, including that it has never been prescribed in humans, that the low-absorption safety argument is contested, and that high prolonged doses can damage blood, nerves and liver.

Fenbendazole has been used for more than 40 years in animals (dogs) and has not been prescribed to humans, so safety in humans cannot be guaranteed

Article body (unpaginated)

Lee Han-soo (Korea Biomedical Review), 2019-10-28: The Korean food-safety ministry's detailed warning against fenbendazole for cancer, including that it has never been prescribed in humans, that the low-absorption safety argument is contested, and that high prolonged doses can damage blood, nerves and liver. Document type: news report quoting the Ministry of Food and Drug Safety and the Korean Cancer Association directly. Key statements as printed: 'All drugs, including anticancer drugs, needs to prove its safety and efficacy through human clinical trials'; the anticancer effect 'are the results of tests on cells and animals, not humans'; the ministry 'stressed that fenbendazole had not been tested in humans and that there were conflicting reports, including studies that state that the drug promotes liver tumors.' This is the Korean regulator's position in its own words as reported, not a formal guideline document; no PDF notice was located. No dose, population, funder or conflict fields apply. Study type: news.